Seegene Awarded Patent for Haplotyping Using Multiplex PCR

Haplotyping genetic screening technique promises to accelerate detection of unique personal traits for disease risk and drug response

23-Dec-2008 - USA

Seegene, Inc announced that it has been awarded international patent protection for a break-through technology able to accelerate the detection of highly personal variations in genetic sequences. These genetic variations can identify an individual's risks for a broad range of disorders, such as Alzheimer's disease and coronary artery diseases, or genetic mutations known to cause various cancers.

The patent (WO/2008/143367) issued by the World Intellectual Property Organization covers a novel method for ApoE haplotyping using multiplex PCR. Seegene's proprietary Dual Priming Oligonucleotide (DPO(TM)) technology is being applied to haplotyping - the investigation of the genetic background and phenotype structures of complex diseases.

According to Jong-Yoon Chun, Founder and Chief Executive Officer, Seegene, "This novel approach to haplotyping using the Seegene multiplex platform allows biomedical researchers to cross a barrier that to this point has frustrated many - the exploration of observed patterns of genetic sequences that help us understand how the diverse traits reveal themselves as true risks for individuals."

Other news from the department research and development

Most read news

More news from our other portals

Under the magnifying glass: The world of microscopy